Walker A, Westerdahl J S, Zussman J, Mathis J
University of Utah School of Medicine, Salt Lake City, Utah 84132, USA.
University of Utah, Department of Dermatology, Salt Lake City, Utah 84111, USA.
Case Rep Dermatol Med. 2022 Mar 25;2022:1461145. doi: 10.1155/2022/1461145. eCollection 2022.
Interstitial granulomatous drug reaction (IGDR) is a distinct inflammatory process that often presents as annular, violaceous plaques distributed on the extremities, proximal trunk, and intertriginous areas. The list of drugs implicated for inciting IGDR is growing, but most prominently includes ACE inhibitors, antihistamines, beta-blockers, antidepressants, and anticonvulsants. Ustekinumab is a human monoclonal antibody that targets inflammatory cytokines IL-12 and IL-23 and has been have shown to be effective in treating IGDR. However, we present a case that suggests ustekinumab can also act as an inciting agent for IGDR.
间质性肉芽肿性药物反应（IGDR）是一种独特的炎症过程，常表现为分布于四肢、躯干近端和褶皱部位的环状、紫红色斑块。引发IGDR的相关药物清单在不断增加，但最主要包括血管紧张素转换酶（ACE）抑制剂、抗组胺药、β受体阻滞剂、抗抑郁药和抗惊厥药。乌司奴单抗是一种靶向炎性细胞因子白细胞介素-12（IL-12）和白细胞介素-23（IL-23）的人源单克隆抗体，已被证明对治疗IGDR有效。然而，我们报告了一例提示乌司奴单抗也可作为IGDR激发剂的病例。
